[Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].

To explore the clinical changes in levels of the new clinical marker serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) in patients with chronic hepatitis B (CHB) with long-term antiviral therapy. 100 CHB cases who were initially treated with nucleos(t)ide analogues (NAs) at Peking University First Hospital were included. The levels of alanine aminotransferase (ALT), HBV DNA, hepatitis B e-antigen (HBeAg), and hepatitis B surface antigen (HBsAg) during the follow-up period were measured. The TaqMan-based real-time quantitative PCR method was used to detect serum HBV pgRNA levels. The independent sample -test and Mann-Whitney test were used to compare continuous variables between groups, while Pearson's (2) test and Fisher's exact test were used to compare categorical variables. HBV pgRNA levels decreased significantly in patients who developed virological responses at 48 weeks ( = 54) during subsequent treatment compared to those who did not ( = 46). The HBV pgRNA level was lower in HBeAg-positive patients than in HBeAg-negative patients ( < 0.05 or < 0.01). Patients with higher HBV DNA and HBeAg-positivity levels at baseline had a higher HBV pgRNA level following antiviral therapy. There was no statistically significant difference in HBV pgRNA levels in patients with different HBV pgRNA levels at baseline after antiviral therapy. There was no correlation between serum HBV pgRNA and HBsAg at baseline, but there was a correlation after long-term antiviral therapy, while there was a weak correlation between HBV pgRNA and HBsAg at the fifth and ninth years of antiviral therapy ( = 0.262, = 0.031; = 0.288, = 0.008). HBV pgRNA levels were higher with higher HBV activity in CHB patients with long-term antiviral therapy.